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Background:  During embryonic development, cells often travel long distances to form 
new tissues and organs. To be able to migrate, embryonic cells undergo a process 
known as epithelial to mesenchymal transition (EMT). Once migratory embryonic cells 
reach their destination they undergo the reverse process, mesenchymal to epithelial 
transition (MET) to later differentiate into multiple cell types. This reveals a high 
degree of cell plasticity, referring to the ability of cells to reversibly change phenotype, 
a common feature of embryonic cells. Research indicates that the EMT program is 
reactivated in cancer cells in the delamination from a primary tumor, the first step 
towards the colonization of distant organs to form secondary tumors (metastasis). It is 
the dissemination of cancer cells and the subsequent formation of metastasis that is 
responsible for the vast majority of cancer-associated deaths. Like EMT, recent 
advances show that cancer cells rely on the reactivation of developmental programs 
through MET for the localization and proliferation of disseminating cells.  The embryo 
provides clues to understand the complex cell biology of EMT and MET in cancer and 
move towards improved therapeutic strategies.  
 
Advances:  
Due to the importance of the EMT/MET programs in normal development for the 
generation of tissues and organs as well as its role in cancer, stringent regulatory 
mechanisms are needed. Multiple extracellular signals converge in the activation of 
transcription factors (EMT-TFs) that can trigger the full EMT program. In addition, 
epigenetic and splicing programs as well as microRNAs regulatory networks regulate 
epithelial plasticity towards EMT or MET.  As differentiated normal and cancer cells can 
re-enter an undifferentiated stem-like state, another level of cell plasticity has become 
apparent, helping to understand complex cell behaviors and interactions.  
 
Outlook: Technical advances in noninvasive in vivo imaging of embryos will help define 
cell behavior and plasticity in normal development, fundamental to understand 
congenital malformations. This knowledge will undoubtedly facilitate the study of 
tumor progression in animal models of cancer. Cancer cells can also be directly 
interrogated about their plastic states in molecular terms after purifying and analyzing 
circulating or disseminated single cells from animal models and also from patients, 
helping in the design of improved therapies. With respect to antimetastatic therapies, 
inhibiting EMT may be counterproductive in tumors that disseminate early, as rather 
than preventing metastasis, it could favor the formation of secondary tumors from 
already disseminated cells. Strategies aimed at targeting cancer stem cells are very 
promising but it is important to bear in mind that new cancer stem cells can be 
produced from differentiated non-stem bulk tumor cells.  
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tumors 
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Towards improved metastatic therapeutic strategies 
 
 
 
Figure Legend 
Epithelial plasticity in 3D cultures. Epithelial cells (MDCK) form ducts when grown on 
3D-matrices resembling the in vivo microenvironment (top). When grown under 
identical conditions, MDCK cells expressing Prrx1 (an EMT inducer) form networks of 
mesenchymal cells (bottom). Note the dramatic phenotypic change that is 
accompanied by the acquisition of motility and invasive properties. Blue, nuclei 
revealed by DAPI staining; Red, Actin filaments as seen after phalloidin binding; Green, 
E-cadherin (epithelial marker) in top panel and Vimentin (mesenchymal marker) in 
bottom panel.   
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During embryonic development, many cells are born far from their final destination 
and must travel long distances. To become motile and invasive, embryonic epithelial 
cells undergo a process of mesenchymal conversion known as epithelial to 
mesenchymal transition (EMT). Likewise, EMT can be seen in cancer cells as they 
leave the primary tumor and disseminate to other parts of the body to colonize 
distant organs and form metastases. In addition, through the reverse process (MET), 
both normal and carcinoma cells revert to the epithelial phenotype to respectively 
differentiate into organs or form secondary tumors. The parallels in phenotypic 
plasticity in normal morphogenesis and cancer, highlight the importance of studying 
the embryo to understand tumor progression and to help in the design of improved 
therapeutic strategies. 
Cellular plasticity refers to the ability of cells to reversibly change their 
phenotype. An example is seen in early metazoan embryogenesis, where epithelial 
cells take on mesenchymal characteristics, a process termed epithelial to mesenchymal 
transition (EMT). The EMT implies the conversion of an epithelial cell into a 
mesenchymal cell with the ability to migrate and invade adjacent tissues. Through the 
associated changes in adhesion and behavior cells can move into the interior of the 
embryo, travel long distances and participate in the formation of internal organs (1). 
Importantly, the latter implies the reversibility of the EMT, as when cells arrive to their 
destination they usually revert to the epithelial phenotype undergoing a mesenchymal 
to epithelial transition (MET) to settle, proliferate and differentiate into different 
organs (2) (Figure 1).  
 The hallmarks of the EMT can be summarized as follows: loss of cell-cell 
junctions, loss of apico-basal polarity and acquisition of migratory and invasive 
properties (3) (Figure 1). This phenotypic change is accompanied by a dramatic change 
in cell behavior (see Suppl. Movies) and is triggered in response to extracellular signals 
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by the activation of one or several transcription factors belonging to different families 
including Snail, Twist, Zeb and others (4), generally termed EMT-TFs (5). These EMT-TFs 
elicit the EMT program by repressing the epithelial phenotype, enhancing 
mesenchymal traits including motility and inducing the ability to degrade the 
basement membrane and the extracellular matrix in general. In addition, they also 
impinge into other basic cellular processes that help maintain the mesenchymal 
phenotype, the efficacy of migration and to survive in adverse environments. As such, 
EMT-TFs attenuate proliferation and protect from cell death activating survival 
signaling cascades (2) (Figure 1). Due to the pivotal role of E-cadherin loss, EMT-TFs are 
sometimes referred to as E-cadherin repressors and also, a decrease in functional E-
cadherin is often associated with the activation of EMT. However, it is important to 
bear in mind that the EMT program and EMT-TFs are much more than E-cadherin 
transcriptional repressors, that E-cadherin downregulation (or endocytosis) is not 
necessarily associated with the EMT program and that E-cadherin re-expression is not 
sufficient to revert the fibroblastic phenotype (6).  
When cells that escape from carcinomas are converted into mesenchymal cells 
with migratory and invasive properties, this can be considered an EMT (2, 3) and many 
EMT-TFs have been characterized that operate during tumor progression (7). However, 
the relevance of the EMT in cancer biology has been a matter of debate (8). The 
application of sophisticated imaging techniques to animal models and the 
characterization of circulating tumor cells (CTCs) from patients as cell with an EMT 
signature have provided evidences that the EMT also occurs during the dissemination 
of cells from a primary tumor (9-12).  
  Since the EMT can also endow cells with stem cell properties, and given that 
cancer can be initiated, maintained and propagated by stationary and motile cancer 
stem cells (CSC; 5, 13), a new field of study has emerged that requires the concerted 
effort of developmental biologists and cancer researchers. However, even though 
developmental and pathological EMTs have many common features they also have 
obvious differences, leading to the classification of three different EMT types (14). 
Type 1 refers to developmental EMTs, type 2 to those related to wound healing, tissue 
regeneration and organ fibrosis and type 3 refers to the EMT associated with cancer. 
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Developmental EMTs imply the conversion of epithelial into mesenchymal cells, but 
embryos lack inflammatory responses, typical of Type 2 and 3 EMTs that occur in the 
adult (14, 15). Type 2 EMT is also characterized by the appearance of myofibroblasts 
with the ability to secrete an excess of extracellular matrix molecules in response to 
inflammation (14). In contrast to the situation in embryos, in cancer cells and during 
regeneration, the acquisition of a mesenchymal state in fibrosis can be considered as 
an end stage, which leads to organ degeneration and failure (Figure 1). During cancer 
progression, tumor cells undergo type 3 EMT, which in addition to invasion and 
motility involves intravasation of delaminated cells into lymphatic and blood vessels, 
and their subsequent extravasation. The intravasation and extravasation steps do not 
occur in fibrosis and do have obvious parallels with the migratory processes undergone 
by embryonic cells. In this review I will focus on the similarities, in particular between 
embryonic and cancer cells, and how the latter rely upon developmental programs, 
not only to delaminate from the initial tumor but also, to later colonize distant sites. 
The common theme of epithelial cell plasticity unifies both events.  
 
Global cellular programs regulate epithelial plasticity 
EMT is triggered by many extracellular signals and agents both in embryos and in 
cancer cells. The most potent inducers are members of the TGFβ/BMP family, but also 
Wnt, Notch, epidermal growth factor (EGF), fibroblast growth factor (FGF), hypoxia, 
obesity, alcohol, nicotine, UV light and others (reviewed in 2). Such pathways and 
agents may act alone or in combination, and the response is dependent on the cell 
context (2). The response to such signals converges on the activation of the EMT-TFs, 
which can cooperate to induce or maintain the mesenchymal phenotype (4, 16). The 
existence of many EMT-TFs provides robustness to the system ensuring the 
implementation of the EMT program during embryonic development (1, 17). Analyzing 
regions where EMT is induced in embryos indicates that Snail expression normally 
precedes the expression of other factors, which are more relevant for the maintenance 
of the mesenchymal phenotype (2, 4). This temporal hierarchy of EMT-TF activation 
and cooperation and also seem to operate in tumors, as observed for Snail factors and 
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Twist in breast epithelial cells and breast cancer progression (16, 18-20). Once 
activated, EMT-TFs can, in turn, activate the same signaling pathways to generate 
positive regulatory autocrine loops that help maintain the mesenchymal phenotype 
both in normal and transformed breast stem cells (21). 
Since EMT may be extremely deleterious when aberrantly activated in the adult 
(3) it needs to be very tightly regulated to ensure epithelial homeostasis. Besides the 
transcriptional level, there is also post-transcriptional, post-translational and 
epigenetic control, including a splicing program specifically associated with the 
epithelial phenotype and regulation by non-coding RNAs (recently reviewed in 22-24, 
Figure 1). The epigenetic, splicing and microRNA networks operating during EMT are 
now being defined at the whole genome level, both in embryos and cancer cells (25-
28), identifying global regulatory programs that control the EMT. Such programs 
provide specificity and robustness through their phenotypic impact on each aspect of 
the EMT both in the embryo and in cancer cells (reviewed in 17, 24) (Figure 1).  
 
EMT in embryonic development and the delamination of cancer cells from primary 
tumors 
The internalization of cells from the surface of the embryo to form organs often 
involves an EMT. Cells disrupt cell-cell adhesion contacts within the primitive epithelial 
layer and ingress. The best studied examples are the ingression of mesendodermal 
precursors at the primitive streak in amniotes and the delamination of the neural crest 
(Figure 2), but it is worth noting that many additional EMT processes exist in the 
embryo, as with the exception of the anterior central nervous system and the 
epidermis, all vertebrate adult tissues originate from cells that underwent at least one 
EMT.  The best evidence of EMT in cancer comes from the observation of single cells 
delaminating from primary tumors (9) and from the finding that circulating and 
disseminated tumor cells from patients (CTCs and  DTCs, respectively) show EMT 
features and a high degree of epithelial plasticity (10,11) (Figure 2).  
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EMT in development and disease is not necessarily an “all or nothing” 
transition, but partial EMT can occur, where cells share epithelial and mesenchymal 
traits. Partial EMTs occur during Drosophila gastrulation, the early migration of groups 
of neural crest cells in anamniotes (amphibian and fish). These cell movements are 
sometimes referred to as collective migration to indicate that cells move in a 
coordinated manner while maintaining some cell-cell contacts (29). However, in terms 
of molecular mechanisms, during these three processes cells have engaged into the 
EMT program, downregulating E-cadherin transcription and losing apico-basal polarity 
upon activation of EMT-TFs (3). Partial EMTs are also observed in the epithelial 
component of carcinosarcomas (30) and at intermediate states during the progression 
of organ fibrosis, when parenchymal (epithelial) cells have activated the EMT program 
and show both epithelial and mesenchymal markers (31).  
  Cell movements can also occur in the absence of an EMT, when cells move 
while maintaining epithelial integrity. Examples of this type of movement include the 
migration of the lateral line primordium in the zebrafish embryo (Figure 2) and that of 
border cells in the Drosphila egg chamber (32). Cells do not express EMT-TFs, maintain 
cell junctions (i.e. including E-cadherin expression) and normally also maintain apico-
basal polarity. These movements can also occur in cancer, when tumor cells invade 
without segregating from the invasive front (Figure 2), and these are able to colonize 
lymph nodes. However, in contrast to cancer cells that have undergone an EMT, they 
are not able to intravasate into blood vessels, to later develop blood-borne distant 
metastasis (33).  
 
Reversal of developmental EMTs for organ formation  
As noted above, developmental EMTs are reversible (34). As such, the cells that go 
through so called primary EMTs in the embryo later undergo the reverse process, MET, 
in order to differentiate into multiple cell types. Early mesodermal cells, generated by 
EMT and  located at different medio-lateral levels of the embryo (axial, paraxial, 
intermediate and lateral plate mesoderms), condense into transient epithelial 
structures through MET to give rise to the notochord, the somites, the primordia of the 
urogenital system, and the splanchopleura and somatopleura, respectively (Figure 3). 
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In the majority of these structures a second round of EMT is completed. For example, 
the dorsal somite converts into the dermal and myotomal mesenchyme, which will 
give rise to components of the dermis and the muscle satellite cells. The ventral part 
will become the mesenchymal sclerotome that later generates the vertebrae, the ribs 
and the tendons (Figure 3). In turn, precursor cells of endodermal organs such as the 
pancreatic endocrine cells migrate upon undergoing EMT and revert this migratory 
phenotype through a MET to form the Langherham islets. A striking example of 
epithelial plasticity is the development of the cardiac valves, for which the initial 
mesenchymal precursors are specified at gastrulation stages and they must undergo 
three consecutive rounds of EMT/MET (2).  
Although many signaling pathways have been identified for EMT (2),  the 
signals involved in the induction of MET have not been well characterized in embryonic 
development. The most studied and amenable processes are those associated with the 
epithelialization of the paraxial and intermediate mesoderm to form the somites and 
the precursors of the renal system, respectively. An increasing gradient of BMP 
signaling along the medio-lateral axis patterns the different mesoderms, with lower 
concentration specifying the paraxial mesoderm. BMP7 counteracts TGFβ signaling and 
is the most prominent known epithelializing agent, with examples seen during kidney 
development (35), during the reprogramming of fibroblasts to induced pluripotent 
stem cells (iPSC; 36), in mouse models of renal fibrosis (37) and in cancer cells (38). 
Eph/Ephrin signaling is also involved in the epithelialization of somites (39) and Wnt 
signaling is required for MET during nephron development (40).  
For nearly all MET processes, there is a concomitant downregulation of the 
corresponding EMT-TFs (i.e. 41, 42). This downregulation is accompanied by the 
appearance of specific epithelial markers that are associated with differentiation into 
the distinct tissues and organs. In the case of the epithelialization of the somitic and 
pronephric tissues, MET is associated with the induction of Paraxis and Pax2, 
respectively.  
 
Reversal of EMTs for metastatic colonization 
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Despite the observations above, it is not universally accepted that tumor cell 
dissemination is related to a change in cell identity (i.e. a requirement for EMT, see 8) 
but rather, it might rely on mutations that weaken the cell-cell adhesion of cancer 
cells. Nevertheless, it is clear that carcinoma metastases usually adopt a well-
differentiated epithelial phenotype. Ironically, this is one of the arguments used to 
dismiss the importance of the EMT in cancer progression. However, the differentiated 
phenotype of metastases reflects the epithelial plasticity implicated in tumor 
progression, in order words, the reversion of EMT firstly suggested by Brabletz and 
colleagues (43) and again resembling the situations described during embryonic 
development (34).  
As in the embryo, MET concurs with the downregulation of EMT-TFs in cancer 
cells. MET not only implies a reversion to the epithelial phenotype but also an increase 
in cell proliferation, important for the growth of the secondary tumor. Several 
transcriptional repressors have been recently identified that can repress EMT-TFs, 
including Kruppel-like factor 17 (KLF17, 44), E74-like factor 5 (ELF5, 45) and Single-
minded 2s (SIM2s, 46). Both ELF5 and SIM2s repress Snail2 expression. Conversely, 
Snail represses Single-minded during Drosophila gastrulation (47), likely revealing an 
additional regulatory loop in the control of epithelial plasticity. 
Complex regulatory loops also control epithelial plasticity post-transcriptionally, 
as numerous microRNAs are integrated into EMT/MET regulatory networks (22, 24). 
Double-negative feedback loops have been described between EMT-TFs (Snail, Zeb and 
Gata3 factors) and several miRs, including members of the miR-200 family and miR-34a 
(48-50), which promote MET and protect the epithelial phenotype (Figure 4). Recently, 
an additional microRNA has been added to this network, as miR-22 promotes EMT and 
cancer progression by indirectly repressing miR-200 (51) and miR-506 has been 
identified as a new node promoting MET (28) (Figure 4).  
While TGFβ is a potent inducer of EMT-TFs, the tumor suppressor p53 activates 
miR-34a and miR-200 (50, 52) (Figure 4). The latter can be antagonized by the 
opposing role of mutant p53, which activates Zeb1 trough the repression of miR-130 
(53). Another p53 family member, p73 and its truncated antagonistic from DNp73, also 
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play opposing roles in tumor progression as while p73 behaves as a tumor suppressor, 
DNp73 induces EMT (54). Going back to the mentioned microRNAS, although much 
less is known about their function during embryonic development, it is clear that miRs 
help the establishment of embryonic territories (55) and that a double-negative 
regulatory loop is established between miR-200 and Sox2 transcription factor during 
neuronal differentiation (56). The expression pattern of miR-200 in developing 
embryos is compatible with its role in preserving the epithelial phenotype and 
promoting MET.   
MET induction by miR-200 was shown to promote breast cancer metastasis (57) 
in agreement with earlier findings indicating that MET facilitates bladder cancer 
metastasis (58) and the observation that myeloid cells induce a MET in the metastatic 
niche (59). However, until very recently a requirement for epithelial plasticity and the 
reversion of EMT had yet to be directly assessed in vivo. 
In an elegant study using a spontaneous squamous cell carcinoma model in 
mice carrying skin-specific inducible Twist, it was shown that Twist-mediated EMT is 
sufficient to promote the dissemination of cancer cells into the bloodstream. Yet more 
importantly, it was shown in this model that Twist needs to be downregulated for 
metastasis to occur (60). Further in vivo evidence for epithelial plasticity and the 
requirement of MET has been found in the progression of breast cancer to the 
metastatic state. EMT mediated by an EMT-TF, the homeobox and paired-related Prrx1 
factor, needs to be reverted, and Prrx1 loss is required for metastatic colonization (16). 
Therefore, a reversible EMT seems to be necessary for the metastasis of primary 
carcinomas, revealing a developmental program that is reactivated by cancer cells in 
order for them to successfully complete the final step of the metastatic cascade, the 
formation of macrometastasis. 
 
Uncoupling EMT and stemness  
It has been found that EMT can confer stem-like properties on cells (61, 62). This is 
consistent with the concept of “migratory cancer stem cells” (63) and provides a link 
between the EMT program and the characteristics associated with cancer stem cells 
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(CSC), i.e. self-renewal and the capacity to seed secondary tumors and produce 
differentiated non-stem cells (5).  However, the relationship between EMT and 
stemness is another controversial issue in tumorigenesis, as it was later shown that 
fibroblasts must undergo a MET to complete the initial reprogramming of fibroblasts 
to iPSCs (36, 64). Again, help may come from development, although CSCs differ from 
canonical embryonic stem cells (ESCs) in that they only revert to the phenotypes of the 
primary tumor and therefore, they have a more restricted potency than both ESCs and 
iPSCs (65). 
The need for a MET during reprogramming is consistent with the epithelial 
nature of ESCs. In fact, the “Yamanaka factors” (Sox2, Klf4, Oct4 and Myc) act together 
with BMP7 to repress TGFβ signaling and EMT-TFs to revert fibroblasts to the epithelial 
phenotype (64). In agreement with this, both Snail1 and Prrx1 are downregulated 
during reprogramming before cells acquire pluripotency genes (65). In line with the 
incompatibility of a stable EMT phenotype and metastatic colonization, Celià-Terrasa 
and colleagues (67) have shown that EMT can suppress tumor-initiating abilities (TICs) 
in epithelial cells. Together, these results link the MET with stem-like properties, rather 
than EMT with stemness as proposed previously. A plausible explanation for this 
apparent contradictory data may be that epithelial plasticity and stemness are 
regulated independently. Indeed, the MET undertaken during reprogramming of 
fibroblasts requires continuous presence of the Yamanaka factors and it does not 
initially involve the acquisition of stemness, which represents a later event (36). In 
addition, one of the EMT-TFs, Snail2, cooperates with Sox9 in the acquisition of the 
mesenchymal mammary stem cell state, although it seems that Snail2 is mainly 
involved in the induction of EMT and Sox9 is responsible for the entry into the stem 
cell state (68). Further evidence of such independent regulation comes from the 
analysis of Prrx1, which unlike “classical EMT-TFs” (Snail, Twist, Zeb factors) induces 
EMT without concomitantly inducing CSC properties. By contrast, it is the loss of Prrx1 
that facilitates self-renewal and mammosphere-forming ability in breast cancer cells 
(16), simultaneously inducing MET and tumor-initiating capacity, both favoring 
metastatic colonization.  
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 How Prrx1 downregulation is achieved at the metastatic niche and how tumor 
initiating capacity is maintained upon the downregulation of EMT-TFs linked to 
stemness (Snail-type) is a matter of future investigation (Figure 5). Another pending 
issue is whether the two EMT types are parallel or exclusive processes in a particular 
tumor.  On the one hand, Prrx and Snail do not show any correlation in datasets from 
patients. However, Prrx1 and Twist are correlated, and in these cases, Prrx1 prevails 
(16) as PRRX downregulation is sufficient to induce MET and CSC properties. It is 
possible that both types (Snail and Prrx) could co-exist, as depicted in Figure 5, but 
information is still lacking. On the other hand, isolated CTCs depict both EMT and CSC 
traits (10, 11), suggesting that they might not include the Prrx1 type. This has not been 
specifically addressed but it is likely that in purified CTCs Prrx-positive cells are 
underrepresented, as they are fully mesenchymal and might have escaped isolation 
with current purification protocols, which use epithelial markers to identify CTCs (10, 
11).  
In summary, data accumulated over the last few years indicate that EMT-TFs 
are developmental factors that when aberrantly activated in tumors initiate the 
invasion-metastatic cascade. This finding also favors the cancer stem cell versus the 
clonal evolution model by which successive mutations accumulate in a tumor providing 
a defined phenotype (69). However, two additional issues need to be discussed here. 
On the one hand, stemness is also a plastic state during tumor progression whereby 
both stationary and migratory CSCs can co-exist (13).  
On the other hand, there are different subsets of EMT-TFs that while all able to 
induce the mesenchymal phenotype, decrease proliferation and promote invasion, 
they can either provide or repress CSC properties (classical EMT-TFs vs Prrx1, 
respectively), or in other words, they can either promote or repress  tumor initiating 
capacities. The bottom line is that (i) EMT-TFs need to be downregulated for 
metastasis to form, which implies reversion to the epithelial phenotype and increased 
proliferation (Figure 5) and (ii) the regulation of stem cell properties is independent 
from that of epithelial plasticity. Indeed, malignancy by cancer cells require the 
reversion to the epithelial phenotype and the maintenance of a “stemness” state (70), 
which may be achieved when the Prrx1-type of EMT-TFs is repressed (16) and/or when 
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Connective Tissue Growth Factor (CTGF), recently described as both MET inducer and 
stem-like properties enhancer, is activated in cancer cells (71) (Figure 5).  
 
EMT/MET in cancer: Conflicting data or just plasticity? 
The high degree of epithelial plasticity observed during cancer progression 
together with the independent regulation of EMT and stemness has several 
implications. EMT-related invasion plus dissemination is required but it is not sufficient 
for completing the metastatic cascade, and therefore invasive and metastatic may not 
be equivalent terms.   
In agreement with the requirement for invasion and dissemination for 
metastasis formation, the presence of CTCs has prognostic and predictive value in 
breast cancer patients (72). Accordingly, abrogating EMT-TFs such as Snail factors in 
cancer cells, make these cells less prone to invade and later generate metastasis when 
injected in mice (18). However, constitutive expression of Snail or Twist also 
suppresses metastasis formation (60, 67) as EMT-TFs must be downregulated for 
metastasis to form (60, 16). Rather than representing a paradox, these data simply 
reflect the plasticity of epithelia and the dynamics of the whole metastatic process, 
resembling that of embryonic cell migration to populate distant territories. Thus, while 
the EMT is associated with the early steps in metastasis, i.e. delamination, invasion and 
intravasation, it is not associated with metastatic colonization. Indeed, there is no 
association between the expression of Snail or Twist in primary tumors and relapse-
free survival in patients with breast or lung squamous carcinomas (16).  This should be 
born in mind when referring to the role of different elements in tumor progression 
and, consequently, avoid the use of the term “invasive and metastatic” for factors 
involved in the acquisition of invasive properties by cancer cells. A similar situation 
applies when we contemplate embryonic development. The EMT-TFs are expressed in 
the embryo wherever EMT processes take place. However, EMT-TFs are not expressed 
in the derivatives of these migratory populations, since once embryonic cells reach 
their destination to differentiate into distinct tissues, the EMT inducers are repressed. 
Thus, EMT-TFs are related to cell behavior rather than to cell fate and hence, their 
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expression is only transient. Accordingly, EMT-TFs cannot be used as markers of 
differentiated cell populations, the equivalent of differentiated distant metastases. 
The description of signals that downregulate EMT-TFs at the metastatic sites awaits 
further investigation but it is clear that interactions between CSCs and the tumor 
microenvironment dictate both EMT/invasion of the primary tumor (73, 74) and 
colonization at the metastatic niche (57, 58, 74). The EMT program also seems to help 
recently extravasated cells to extend filopodium-like protrusions (FLPs), to interact 
productively with the niche, promoting homing and proliferation (75). Cytokines are 
important to modify both microenvironments as they are fundamental to recruit 
mesenchymal stem cells (MSCs) and inflammatory cells. Indeed, the stroma influences 
metastasis formation and recent data point to the regulation of TGFβ/BMP signaling in 
both the primary tumor and the metastatic niche in colorectal and breast carcinomas 
(33, 76, 77).  
 
Towards improved metastatic therapeutic strategies 
Cell plasticity and heterogeneity in tumor biology also has an impact on the 
design of therapeutic strategies (69). Classical cytotoxic chemotherapy has proven 
beneficial in patients with carcinoma. However, one of the main caveats is the 
appearance of tumor recurrence, associated with acquired multidrug resistance and 
concomitant with the appearance of signs of EMT and stemness in the residual or 
relapsed tumor after chemotherapy. Indeed, resistance to cell death is a property of 
embryonic migratory cells upon undergoing EMT, implemented to promote their 
arrival to their destination (78). A similar strategy is used by cancer stem cells and 
therefore, efforts are being devoted to fighting not only proliferation but also EMT and 
stem cell-like properties to prevent the metastatic disease in cancer patients. 
To target the EMT, the strategy has been to inhibit some of its inducing 
signaling pathways including those of EGFR, PDGFR and TGF-β. Recent data indicate 
that inhibiting the TGF-β pathway might be beneficial in colorectal cancer metastatic 
disease (77). But even if the bulk of the tumor can be significantly decreased, 
chemoresistant stem cells will support the subsequent growth of the tumor. 
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Therefore, different strategies have been used to directly target CSCs, including 
inhibitors of additional pathways such as those triggered by the developmental factors 
Notch, Wnt and Shh, using cytoprotective agents and/or small molecules identified in 
high-throughput screenings.  
Recent data indicate that not only stem cells can generate differentiated cells 
but also that adult normal and (non-stem) cancer cells can re-enter the stem state, 
pointing to a bidirectional conversion between stem and non-stem populations (79, 
80) (Figure 5). This additional plasticity seems to be dependent on the chromatin state 
of the Zeb1 promoter, which is in a bivalent state in non-CSCs so that it can be rapidly 
activated in response to EMT inducing signals to help the conversion of non-CSCs into 
CSCs (81) (Figure 4). Thus, there is a need to adjust therapeutic strategies to this 
superimposed level of cellular plasticity, as combating CSC is unlikely to be sufficient as 
new stem cells can be generated from the remaining differentiated tumor cells. The 
idea is to combine classical chemotherapy with anti-CSC drugs to simultaneously hit 
non-stem cells and CSC in a tumor. 
Finally, it is clear that fully preventing delamination from the primary tumor will 
impede metastasis, which is the principle that has inspired efforts by academia and 
pharmaceutical companies to block the EMT. A recent report shows that this seems to 
be a valid strategy, as observed in a mouse model of ovarian carcinoma (28). 
Nonetheless, in the light of recent data on epithelial plasticity during metastatic 
colonization, and the need for cancer cells to revert to the epithelial phenotype 
through a MET (16, 60), rather than preventing metastasis, inhibiting EMT could favor 
the formation of secondary tumors from already disseminated cells. This is particularly 
important in carcinomas where EMT is a very early event in tumorigenesis, where 
cancer cells have already disseminated before the tumor is diagnosed, as in pancreatic 
and breast carcinomas (82, 83). In contrast, as EMT reversion does not happen during 
the development of the fibrotic disease, therapeutic intervention inhibiting EMT is a 
promising strategy to ameliorate fibrosis and organ degeneration (37). 
 In summary, recent advances reveal an unanticipated degree of cell plasticity 
during the progression of carcinomas to the metastatic state and in the generation of 
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CSCs, reflecting the complex biology of cancer. This concept will undoubtedly influence 
the strategies for therapeutic intervention. Further complexity may arise when 
considering other tumor types. An example is found in melanomas, where recent data 
show that ZEB1 and TWIST1 promote dedifferentiation and are associated with late-
stage melanoma and poor prognosis whereas SNAIL2 and ZEB2 do not behave as 
classical EMT inducers, as they are expressed in normal melanocytes and work as 
tumor suppressors (84). Fortunately, the process of morphogenesis provides clues as 
to how cell plasticity may occur in cancer, including the mechanisms used in the 
maintenance and differentiation of CSCs. Embryos together with cancer animal models 
such as “avatar” mice (carrying cancer cells from individual patients) will help define 
the best therapeutic strategy even on a personalized manner. In general terms, 
although inhibiting EMT may be counterproductive, strategies aimed at targeting 
cancer stem cells are very promising, keeping in mind that new cancer stem cells can 
be produced from differentiated non-stem bulk tumor cells. 
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Figure legends 
 
Figure 1. The control of epithelial plasticity in development and disease. Embryonic 
epithelial cells undergo EMT to migrate and then revert to the epithelial phenotype 
at their destination to give rise to different tissues and organs. After injury, 
epithelial cells undergo a partial EMT to heal the wound.  Later undergo a MET to 
maintain epithelial homeostasis. Likewise, disseminated cancer cells need to return 
to the epithelial state during metastatic colonization, accompanied by the recovery 
of a high proliferation potential for the establishment of a secondary tumor. A MET 
is also required during reprogramming of fibroblasts to iPSCs. The development of 
organ fibrosis also involves EMT, which does not revert and leads to organ 
degeneration and failure. Both developmental and pathological EMTs induce not 
only morphological changes but also provide motility and invasive properties 
together with the ability to overcome safe-guard  mechanisms, leading to cell 
survival and chemotherapy resistance, particularly relevant in cancer patients. 
Global cellular programs, including epithelial-specific splicing, epigenetic 
mechanisms and microRNA regulatory networks are in place to protect epithelial 
homeostasis. EMT, epithelial to mesenchymal transition; MET mesenchymal to 
epithelial transition.  
 
Figure 2.  Cell migration in embryos and tumors. Individual migration occurs after 
epithelial cells undergo EMT, as for neural crest migration during normal 
embryonic development and the delamination of breast cancer cells from the 
primary tumor. Partial EMT can also occur when cells activate the EMT program 
but maintain some contacts with their migrating neighbors. Integrated tissue 
migration implies a decrease in cell-cell adhesion forces but the maintenance of 
epithelial traits including cadherin expresion and apico-basal polarity. This type of 
migration is observed in the developing zebrafish lateral line and in the invasive 
front of some carcinomas. Cells at the invasive front can also activate the EMT 
program, in which case they can be seen delaminating as individual or loosely 
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organized groups of cells. Blue, epithelial cells; Yellow, mesenchymal cells (after 
EMT). 
 
 
Figure 3. Reversibility of EMT during embryonic development. Physiological EMTS are 
reversible. Adult vertebrate tissues with the exception of the epidermis and part of 
the central nervous system are the result of one or several rounds of EMT/MET. 
The figure follows a temporal developmental sequence. 1. The precursors of the 
endoderm and the mesoderm ingress at the primitive streak, a prototypical 
example of primary EMT. 2. The mesodermal precursors migrate to occupy 
different positions along the medio-lateral axis of the embryo to give rise to axial, 
paraxial, intermediate and lateral mesoderm, which upon undergoing MET will 
generate notochord, somites, the urogenital system and the splanchno- and 
somatopleura, respectively. 3. The majority of these epithelial derivatives undergo 
a second round of EMT. The figure exemplifies secondary EMTs showing those 
occurring in the somites (see text). Blue, epithelial cells; Yellow, mesenchymal cells 
after EMT. 
 
 
Figure 4. Epithelial plasticity and microRNA regulatory networks. A-D. Signaling 
pathways mediated by TGF-β or the Notch ligand Jagged induce the expression of 
EMT-TFs (Zeb, Snail, Prrx or Gata3 factors), which are downregulated by a series of 
microRNAs (miR-200, miR-130, miR-34a and miR-506) to protect epithelial 
integrity. Double negative-feedback loops are established in which microRNAs and 
the TFs behave as reciprocal repressors. The tumor suppressor p53 prevents EMT 
by activating miR-200 and miR-34a. In contrast, mutant p53 and miR-22 activate 
EMT by repressing miR-130 and miR-200, respectively. Epigenetic regulation of the 
Zeb1 and miR-200 promoters impinges into their feedback loop.  Zeb promoter 
bivalent state of allows its rapid activation, EMT and re-entry into the CSC state by 
increasing the expression of the surface marker CD44. In contrast, the TET complex 
demethylates miR-200 promoter, thereby favoring MET. Sirtuin 1 (Sirt1) favors 
EMT by cooperating with EMT-TFs in the repression of E-cadherin expression. miR-
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506 is a newly described EMT regulator able to repress several EMT-TFs including 
Snail2 and Prrx-1. Blue: MET related molecules; Yellow: EMT related molecules; 
Pink: CSC markers. 
 
 
Figure 5. Reversibility of EMT during metastatic colonization. Cancer cells delaminate 
from the primary tumor expressing EMT-TFs, which endow them with invasive 
properties to migrate through the extracellular matrix and enter the lymphatic and 
blood vessels. Those migratory cancer cells expressing classical EMT-TFs (Snail, 
Twist and Zeb factors) present CSC properties whereas those expressing Prrx1 do 
not. These two classes of CTCs are depicted although whether the two types of 
EMT occur in parallel or are exclusive for individual tumors has not been shown. 
After extravasation, disseminated tumor cells can colonize distant organs, 
undergoing a MET upon downregulation of the EMT-TFs, which reverts them to the 
epithelial state and increase proliferation. Further work is necessary to characterize 
the signals that downregulate the EMT-TFs while maintaining CSC properties. CTGF 
has been shown to induce MET concomitantly with CSC traits in cancer cells, a 
global effect similar to that produced after Prrx1 downregulation. Stationary cancer 
stem cells can be converted into differentiated tumor cells and dedifferentiation of 
non-CSC can generate cells with tumor initiating capacity. This bidirectional 
conversion (white double arrows) adds a high degree of phenotypic plasticity in 
tumors that requires the design of improved therapeutic strategies.  
 
 
Supplementary movies legends 
 
Movie S1. Epithelial cells are unable to degrade extracellular matrix and migrate.  
Kidney Epithelial (MDCK) cells were suspended in Matrigel (BD Biosciences):Media 
(1:1) and a drop of the mixture was placed onto a glass-bottom culture Petri dish 
(MatTek). The drop was covered with culture medium and incubated in a chamber at 
37ºC and 5% CO2 (Life Imaging Services, Basel, Switzerland) that surrounds an inverted 
confocal Laser Scanning Spectral Confocal Microscope TCS SP2 AOBS  (Leica 
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Microsystems, Heidelberg GmbH). For time-lapse movies, one image was captured 
every 10 min for a total of 17 hr. Movies were assembled using the ImageJ software 
(http://rsbweb.nih.gov/ij/).  
 
Movie S2. Epithelial cells stably transfected with Prrx1 undergo a full EMT, degrade 
extracellular matrix and migrate.  For time-lapse movies, one image was captured 
every 10 min for a total of 17 hr. 
MDCK-Prrx1 cells were cultured and images processed as control cells (see Movie S1 
legend).  
 





